Navigation Links
Sosei Announces Start of AD 923 Phase III Studies in Europe
Date:2/11/2008

TOKYO, Japan, February 12 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), a biopharmaceutical company, today announces that it has commenced Phase III studies for its fentanyl sublingual spray (AD 923), an opioid analgesic for the treatment of cancer breakthrough pain.

The trial is a multi-centre, randomised, double-blind, double-dummy, crossover study to evaluate the safety and efficacy of AD 923 against an active comparator (morphine sulphate immediate release (MSIR)) for the treatment of breakthrough pain in patients with malignancies. The primary endpoint is the well established summary of pain intensity difference (SPID) measure over the first 30 minutes from initial dosing.

Overall, the European Phase III programme will involve some 300 patients in two studies, involving an active comparator, across 10 European countries. These will then be followed by a single combined open label study to assess the long term effectiveness, safety and tolerability of AD 923.

In June 2006, Sosei entered into an agreement with Mundipharma International Corporation Limited for the development and commercialisation of AD 923 in Europe and other international markets, excluding North America and Japan. Sosei is currently evaluating its commercialisation options for the un-partnered territories.

Mr Shinichi Tamura, President & CEO of Sosei, said: "I am delighted that we are able to announce the start of Phase III studies. AD 923 has been optimised to meet the well recognised need for a safe and effective method of delivering fentanyl for the rapid relief of breakthrough pain in malignant and also non-malignant conditions."

Notes for Editors:

About Sosei

Sosei Group Corporation is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for establish
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Sosei and Vectura Announce Start of Phase II Studies of QVA149 for the Treatment of COPD
2. Sosei Announces Update on Phase I Trials for SD118
3. Sosei Announces Approval to Start AD 923 Phase III Studies in Europe
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2015)... NY (PRWEB) May 24, 2015 The ... Sunday, May 24th in San Diego at Petco Park. ... North America. On May 20th, they had a warmup ... At their preview show in Los Angeles, this beloved band ... they also played fan favorites such as "Jumping Jack Flash," ...
(Date:5/24/2015)... Scientists with Cardno ChemRisk, a scientific consulting firm, ... that may have raised the risk of mesothelioma for ... an article on the research. Click here to ... asbestos levels well above OSHA safety guidelines when they ... “Asbestos compliance sampling data associated with the construction, automotive ...
(Date:5/24/2015)... 24, 2015 Indiana Fiber Network, LLC ... Midwest Telecom of America, Inc. (MTA) has selected IFN ... Cory Childs, IFN Enterprise Sales Manager, fiber route diversity ... “IFN’s fiber transport provides MTA with the diverse fiber ... Tier 1 Internet and voice carriers located at Henry ...
(Date:5/23/2015)... 2015 On Saturday, May 23, 2015, over ... for Branches Florida City exactly five years to the day ... 2010. , A large fire tore through the Branches United ... 2010 in the middle of the night as neighbors, staff ... declared arson even though it is suspected that the fire ...
(Date:5/23/2015)... York, NY (PRWEB) May 23, 2015 ... announced that, “the company has been the target ... as a part of the company’s ongoing Information Technology ... on health insurers.” , The most notable attack ... year when Anthem Inc., the nation’s second largest health ...
Breaking Medicine News(10 mins):Health News:The Rolling Stones Tickets in San Diego, Orlando, Minneapolis, Dallas, Pittsburgh, Indianapolis, Atlanta, Detroit, Milwaukee, Kansas City, Columbus, Nashville & Raleigh 2Health News:New Analysis Finds Too Many Employers Ignored OSHA Asbestos Guidelines, According to Surviving Mesothelioma 2Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4
... Medicare Strike Force Since March, WASHINGTON, Oct. 4 ... and operator of Direct Nursing Assistance Inc. of,Medicare fraud, ... and U.S. Attorney R. Alexander Acosta of the Southern ... trial, Rodolfo Aenlle, 47, was found guilty on all,counts ...
... IRIDEX,Corporation (Nasdaq: IRIX ) announced the ... the Company,s new independent auditor effective October,2, 2007. ... by the Audit Committee of the Company,s Board ... discussions with several,public accounting firms. BPM replaces PricewaterhouseCoopers ...
... in September Proving Successful, OWINGS MILLS, Md., Oct. ... that based on the current business outlook, the,Company is ... 31,2007. The Company expects to report revenue of $81 ... per diluted share. Previously, the Company,expected to report revenue ...
... part of what is ... nonprofit for teens., WILSONVILLE, Ore., Oct. 4 On Tuesday, October ... furniture,arcade games and supplies. These and other items, unused for at least ... the,Sexual Minority Youth Resource Center (SMYRC). Volunteer crews will move an ...
... Oct. 4 - A new American Heart,Association survey (1) shows consumer awareness ... an all-time high. But consumers still need,some key information to improve how ... the Bad Fats Are The survey shows that:, --While 92 ... jump from 84 percent in 2006 - only 21 percent ...
... revealing how toxic chemicals disrupt gene activity and other ... -- and why some individuals are particularly vulnerable. For ... more likely to experience side effects from certain medications, ... , How can this type of research -- known ...
Cached Medicine News:Health News:Miami Jury Convicts Medical Company Owner of Medicare Fraud 2Health News:Medifast Announces Updated Full Year 2007 Guidance 2Health News:Medifast Announces Updated Full Year 2007 Guidance 3Health News:Medifast Announces Updated Full Year 2007 Guidance 4Health News:Contents of the McGinnis Mansion Refurbishes Portland, Oregon Sexual Minority Youth Center 2Health News:Contents of the McGinnis Mansion Refurbishes Portland, Oregon Sexual Minority Youth Center 3Health News:Americans' Knowledge of Fats Growing But Still Insufficient 2Health News:Americans' Knowledge of Fats Growing But Still Insufficient 3
(Date:5/22/2015)... THOUSAND OAKS, Calif. , May 22, ... today announced the Company has commenced termination ... commercialization of brodalumab with AstraZeneca (LON:AZN, STO:AZN ... investigational IL-17 inhibitor, is in development for ... and axial spondyloarthritis.  The decision was based ...
(Date:5/22/2015)... May 22, 2015 The Assistance Fund announces ... program provides financial assistance for copay to individuals diagnosed ... announce the addition of the Melanoma Copay Assistance Program ... McGreevy , executive director. "With each additional program we ... a world where no one is denied access to ...
(Date:5/22/2015)... May 22, 2015  The U.S. Food and ... -- the first biosimilar product approved in ... toward growth in the contract manufacturing organization (CMO) ... industry is geared to the production of small-molecular ... biopharmaceutical products. The healthcare market research publisher,s report, ...
Breaking Medicine Technology:Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5The Assistance Fund Adds Melanoma Assistance Program 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4
... April 26, 2012 Upsher-Smith Laboratories, Inc. ( ... the pharmacokinetic (PK) profile of USL255, its once-daily, ... 64th Annual American Academy of Neurology (AAN) Meeting.  ... USL255 and equal doses of immediate-release (IR) topiramate ...
... effects of Neupro ® (rotigotine transdermal system) on ... today at the 64th AAN Annual Meeting in New ... data from five, randomized, double-blind,  placebo-controlled trials investigated the ... fatigue in patients with PD. Improvements were observed with ...
Cached Medicine Technology:Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate 2Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate 3Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate 4Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate 5New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinson's disease 2New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinson's disease 3New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinson's disease 4New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinson's disease 5New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinson's disease 6New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinson's disease 7New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinson's disease 8New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinson's disease 9New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinson's disease 10
RapidStrep A test is a qualitative test that detects group A,streptococcal antigen. The test is a rapid, in vitro assay. It is,intended for professional use to help diagnose Strep A,infection i...
... caused by the intracellular parasite Toxoplasma gondii ... or by contract with cat,feces containing oocytes. ... be passed to the fetus through the ... is a cause of mortality and malformation.,This ...
... an immunochromatographic in vitro assay,for detection ... infection.,Infectious mononucleosis (IM) is caused by ... is based on detection of,serum antibodies ... the,heterophile antibodies present in the sera ...
Inquire...
Medicine Products: